FOR YOUR INFORMATION
FDA Looking Into Vytorin and Cancer Risk, but Interim Analysis Reassuring for Patients to Continue With Medication
from Heartwire — a professional news service of WebMD
Michael O'Riordan
August 22, 2008 — The Food and Drug Administration (FDA) has issued a statement informing clinicians about its investigation into the possible link between Vytorin, a combination of ezetimibe and simvastatin (Merck/Schering-Plough Pharmaceuticals), and an increased risk of cancer [1]. At this point, however, the FDA states the review should not prompt patients to stop taking Vytorin or any other cholesterol-lowering drug.
No comments:
Post a Comment